vs

Side-by-side financial comparison of Charles River Laboratories (CRL) and Weatherford International plc (WFRD). Click either name above to swap in a different company.

Weatherford International plc is the larger business by last-quarter revenue ($1.2B vs $995.8M, roughly 1.2× Charles River Laboratories). Weatherford International plc runs the higher net margin — 9.5% vs -1.5%, a 10.9% gap on every dollar of revenue. On growth, Charles River Laboratories posted the faster year-over-year revenue change (1.2% vs -8.3%). Over the past eight quarters, Charles River Laboratories's revenue compounded faster (-1.5% CAGR vs -9.5%).

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

Weatherford International plc is an American multinational oilfield service company, headquartered in the US and operating in 75 countries globally across the oil and natural gas producing regions. The company provides technical equipment and services used for drilling, evaluation, completion, production, and intervention on gas and oil wells.

CRL vs WFRD — Head-to-Head

Bigger by revenue
WFRD
WFRD
1.2× larger
WFRD
$1.2B
$995.8M
CRL
Growing faster (revenue YoY)
CRL
CRL
+9.5% gap
CRL
1.2%
-8.3%
WFRD
Higher net margin
WFRD
WFRD
10.9% more per $
WFRD
9.5%
-1.5%
CRL
Faster 2-yr revenue CAGR
CRL
CRL
Annualised
CRL
-1.5%
-9.5%
WFRD

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CRL
CRL
WFRD
WFRD
Revenue
$995.8M
$1.2B
Net Profit
$-14.8M
$109.0M
Gross Margin
Operating Margin
12.0%
10.7%
Net Margin
-1.5%
9.5%
Revenue YoY
1.2%
-8.3%
Net Profit YoY
-157.2%
42.1%
EPS (diluted)
$-0.30
$1.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRL
CRL
WFRD
WFRD
Q1 26
$995.8M
$1.2B
Q4 25
$994.2M
$1.3B
Q3 25
$1.0B
$1.2B
Q2 25
$1.0B
$1.2B
Q1 25
$984.2M
$1.2B
Q4 24
$1.0B
$1.3B
Q3 24
$1.0B
$1.4B
Q2 24
$1.0B
$1.4B
Net Profit
CRL
CRL
WFRD
WFRD
Q1 26
$-14.8M
$109.0M
Q4 25
$-276.6M
$138.0M
Q3 25
$54.4M
$81.0M
Q2 25
$52.3M
$136.0M
Q1 25
$25.5M
$76.0M
Q4 24
$-214.5M
$112.0M
Q3 24
$69.7M
$157.0M
Q2 24
$94.1M
$125.0M
Gross Margin
CRL
CRL
WFRD
WFRD
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
34.6%
Q2 24
34.5%
Operating Margin
CRL
CRL
WFRD
WFRD
Q1 26
12.0%
10.7%
Q4 25
-28.5%
15.4%
Q3 25
13.3%
14.4%
Q2 25
9.7%
19.7%
Q1 25
7.6%
11.9%
Q4 24
-16.7%
14.8%
Q3 24
11.6%
17.2%
Q2 24
14.8%
18.8%
Net Margin
CRL
CRL
WFRD
WFRD
Q1 26
-1.5%
9.5%
Q4 25
-27.8%
10.7%
Q3 25
5.4%
6.6%
Q2 25
5.1%
11.3%
Q1 25
2.6%
6.4%
Q4 24
-21.4%
8.4%
Q3 24
6.9%
11.1%
Q2 24
9.2%
8.9%
EPS (diluted)
CRL
CRL
WFRD
WFRD
Q1 26
$-0.30
$1.49
Q4 25
$-5.57
$1.91
Q3 25
$1.10
$1.12
Q2 25
$1.06
$1.87
Q1 25
$0.50
$1.03
Q4 24
$-4.17
$1.53
Q3 24
$1.33
$2.06
Q2 24
$1.74
$1.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRL
CRL
WFRD
WFRD
Cash + ST InvestmentsLiquidity on hand
$191.8M
$1.0B
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$2.9B
$1.8B
Total Assets
$7.7B
Debt / EquityLower = less leverage
0.84×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRL
CRL
WFRD
WFRD
Q1 26
$191.8M
$1.0B
Q4 25
$213.8M
$987.0M
Q3 25
$207.1M
$967.0M
Q2 25
$182.8M
$943.0M
Q1 25
$229.4M
$873.0M
Q4 24
$194.6M
$916.0M
Q3 24
$210.2M
$920.0M
Q2 24
$179.2M
$862.0M
Total Debt
CRL
CRL
WFRD
WFRD
Q1 26
$1.5B
Q4 25
$2.1B
$1.5B
Q3 25
$2.2B
$1.5B
Q2 25
$2.3B
$1.6B
Q1 25
$2.5B
$1.6B
Q4 24
$2.2B
$1.6B
Q3 24
$2.3B
$1.6B
Q2 24
$2.4B
$1.6B
Stockholders' Equity
CRL
CRL
WFRD
WFRD
Q1 26
$2.9B
$1.8B
Q4 25
$3.2B
$1.7B
Q3 25
$3.4B
$1.6B
Q2 25
$3.4B
$1.5B
Q1 25
$3.2B
$1.4B
Q4 24
$3.5B
$1.3B
Q3 24
$3.8B
$1.3B
Q2 24
$3.7B
$1.2B
Total Assets
CRL
CRL
WFRD
WFRD
Q1 26
$7.7B
Q4 25
$7.1B
$5.2B
Q3 25
$7.5B
$5.3B
Q2 25
$7.6B
$5.1B
Q1 25
$7.6B
$5.1B
Q4 24
$7.5B
$5.2B
Q3 24
$8.0B
$5.2B
Q2 24
$7.9B
$5.1B
Debt / Equity
CRL
CRL
WFRD
WFRD
Q1 26
0.84×
Q4 25
0.68×
0.86×
Q3 25
0.64×
0.94×
Q2 25
0.70×
1.04×
Q1 25
0.79×
1.17×
Q4 24
0.65×
1.26×
Q3 24
0.62×
1.21×
Q2 24
0.65×
1.33×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRL
CRL
WFRD
WFRD
Operating Cash FlowLast quarter
$41.1M
$136.0M
Free Cash FlowOCF − Capex
$85.0M
FCF MarginFCF / Revenue
7.4%
Capex IntensityCapex / Revenue
5.6%
4.7%
Cash ConversionOCF / Net Profit
1.25×
TTM Free Cash FlowTrailing 4 quarters
$470.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRL
CRL
WFRD
WFRD
Q1 26
$41.1M
$136.0M
Q4 25
$147.5M
$268.0M
Q3 25
$213.8M
$138.0M
Q2 25
$204.6M
$128.0M
Q1 25
$171.7M
$142.0M
Q4 24
$159.4M
$249.0M
Q3 24
$251.8M
$262.0M
Q2 24
$193.5M
$150.0M
Free Cash Flow
CRL
CRL
WFRD
WFRD
Q1 26
$85.0M
Q4 25
$58.6M
$217.0M
Q3 25
$178.2M
$94.0M
Q2 25
$169.3M
$74.0M
Q1 25
$112.4M
$65.0M
Q4 24
$83.7M
$149.0M
Q3 24
$213.1M
$184.0M
Q2 24
$154.0M
$88.0M
FCF Margin
CRL
CRL
WFRD
WFRD
Q1 26
7.4%
Q4 25
5.9%
16.8%
Q3 25
17.7%
7.6%
Q2 25
16.4%
6.1%
Q1 25
11.4%
5.4%
Q4 24
8.4%
11.1%
Q3 24
21.1%
13.1%
Q2 24
15.0%
6.3%
Capex Intensity
CRL
CRL
WFRD
WFRD
Q1 26
5.6%
4.7%
Q4 25
8.9%
4.0%
Q3 25
3.5%
3.6%
Q2 25
3.4%
4.5%
Q1 25
6.0%
6.5%
Q4 24
7.5%
7.5%
Q3 24
3.8%
5.5%
Q2 24
3.8%
4.4%
Cash Conversion
CRL
CRL
WFRD
WFRD
Q1 26
1.25×
Q4 25
1.94×
Q3 25
3.93×
1.70×
Q2 25
3.91×
0.94×
Q1 25
6.74×
1.87×
Q4 24
2.22×
Q3 24
3.61×
1.67×
Q2 24
2.06×
1.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRL
CRL

Service revenue$798.2M80%
Product revenue$197.7M20%

WFRD
WFRD

Middle East/North Africa/Asia$476.0M41%
Europe/Sub-Sahara Africa/Russia$233.0M20%
Latin America$223.0M19%
North America$220.0M19%

Related Comparisons